Advertisement

Palliative Hormonal Treatment in Endometrial Carcinoma

  • K.-D. Schulz
  • J. Hofmann
  • R. Hackenberg
  • G. Emons
  • P. Schmidt-Rhode
  • G. Sturm
Part of the AGO Arbeitsgemeinschaft für Gynäkologische Onkologie book series (AGO)

Abstract

At first sight the description of the palliative hormonal treatment methods in disseminated malignant endometrial tumors is a simple exercise requiring only a few minutes. This anticipation is true if only the presently established therapeutic models are described.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kaiser R: Die Wirkung von Gestagenen beim Korpuskarzinom. Arch. Gynaek. 193: 195, 1959CrossRefGoogle Scholar
  2. 2.
    Kelley RM, Baker WH: Progestational agents in the treatment of carcinoma of the endometrium. New Engl. J. Med. 264: 216, 1961PubMedCrossRefGoogle Scholar
  3. 3.
    Richardson GS, Mac Laughlin DT: Hormonal biology of endometrial cancer. UICC Technical Report Series 42, 1978Google Scholar
  4. 4.
    Brooks SC, Christensen C, Meyers S, Corombos J, Pack BA: Endocrine implications of endometrial estrogen sulfurylation. In: “Steroids and endometrial cancer”. Jasonni VM, Nenci J, Flamigni C (eds). Raven Press, New York, p. 145, 1983Google Scholar
  5. 5.
    Pannuti F, Giovannini M, Martoni A, Fruet F, Rubino J, Vecchi F, Zanichelli L, Pieromaldi S: Effects of high dose oral medroxyprogesterone acetate (MPA) on plasma levels of T3, T4, TSH, LH, FSH, PRL, 17ß- oestradiol, testosterone and aldosterone. IRCS Med. Sei, 8: 764, 1980Google Scholar
  6. 6.
    Pannuti F, Martoni A, Camaggi CM et al: High dose medroxyprogesterone acetate in oncology: history, clinical use and pharmacokinetics. In: “Int. Symp. Medroxy progesterone Acetate”. Cavalli F et al (eds), Excerpta Medica, p. 5, 1982Google Scholar
  7. 7.
    Schulz KD, Schmidt-Rhode P, Sturm G: High dose medroxyprogesterone acetate in breast cancer-present state of knowledge. In: “Progress in hormono- and chemotherapy”. Robustelli della Cuna G, Nagel GA, Lanius, P (eds) Kehrer, Freiburg, p. 21, 1985Google Scholar
  8. 8.
    Schulz KD, Schmidt-Rhode P, Zippel HH, Sturm G: New Concepts of Adjuvant Drug Treatment in Endometrial Cancer. In: “Endometrial Cancer”. Schulz KD, King RJB, Pollow K, Taylor RW (eds), Zuckschwerdt, München, p. 169, 1987Google Scholar
  9. 9.
    Swenerton KD: Antioestrogens for the treatment of endometrial cancer. In: “Endometrial Cancer”. Schulz K-D, King RJB, Pollow K, Taylor RW (eds), Zuckschwerdt, München, p. 165, 1987Google Scholar
  10. 10.
    Jordan VC: Resistance to antioestrogen therapy: a challenge for the future. In: Cavalli F (Ed): Endocrine therapy of breast cancer III. Springer Berlin, p.51–60, 1989CrossRefGoogle Scholar
  11. 11.
    Schulz KD, Sturm G, Schmidt-Rhode P, Hackenberg R, Künzig HJ: Pharmakokinetik und Pharmakodynamik der Antiöstrogene. In: Kubli F et al (Eds): Neue Wege in der Brustkrebsbehandlung. Zuckschwerdt München, p. 62, 1983Google Scholar
  12. 12.
    Murray RML, Pitt P: Treatment of advanced metastatic breast cancer, carcinoma of the prostate and endometrial cancer with aminoglutethimide. In: “Aminoglutethimide as an aromatase inhibitor in the treatment of cancer”. Nagel GA, Santen RJ (eds) Hans Huber Publishers Bern, p. 109, 1984Google Scholar
  13. 13.
    Santen RJ, Lipton A, Harvey H, Boucher AE, Henderson C: Pharmacological mechanisms of oestrogen Suppression with aminoglutethimide in women with breast cancer. In: “Aminoglutethimide as an aromatase inhibitor in the treatment of cancer”. Nagel GA, Santen RJ (eds), Hans Huber Publishers Bern, p. 38, 1984Google Scholar
  14. 14.
    Schulz KD, Rück A, Zippel HH, Hofmann J, Hackenberg R, Schmidt-Rhode P, Hölzel F, Pfisterer Y: Endometrial Cancer, Advances in Clinical Oncology 3: 95, 1988Google Scholar
  15. 15.
    Bonte J, Decoster MJ, Ide P, Billiet G: Hormonoprophylaxis and Hormonotherapy in the treatment of Endometrial Adenocarcinoma by means of Medroxyprogesterone Acetate. Gynecol. Oncol. 6: 60, 1978PubMedCrossRefGoogle Scholar
  16. 16.
    Bonte J. Hormone dependency and hormone responsiveness of endometrial adenocarcinoma to estrogens, progestogens and antiestrogens. In: “Role of medroxyprogesterone in endocrine- related tumours”. Campio L, Robustelli della Cuna G, Taylor RW (eds) Raven Press, New York, p. 141, 1983Google Scholar
  17. 17.
    Robustelli della Cuna G: Comprehensive guide to the therapeutic use of medroxy progesterone acetate in oncology. Farmitalia Press, Milano 1987Google Scholar
  18. 18.
    Hackenberg R, Hofmann J, Wolff G, Hölzel F, Schulz KD: Down-regulation of androgen receptor by progestins and interference with estrogenic or androgenic stimulation of mammary carcinoma cell growth. J Cancer Res Clin Oncol (in press) 1990Google Scholar
  19. 19.
    Hofmann J, Kunzmann R, Drescher A, Hackenberg R, Hölzel F, Schulz KD: Growth regulation of human endometrial carcinoma cells in vitro by steroid hormones and growth factors. Proc Internat Congr Hormones and Cancer, Raven Press, New York, p. 452, 1988Google Scholar
  20. 20.
    Rendina GM: High dose medroxyprogesterone acetate in the therapy of endometrial carcinoma. In: “Medroxyprogesterone acetate (MPA) in the therapy of hormone-dependent tumours”. Nagel GA, Robustelli della Cuna G, Lanius P (eds), Kehrer Freiburg, p. 161, 1984.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • K.-D. Schulz
  • J. Hofmann
  • R. Hackenberg
  • G. Emons
  • P. Schmidt-Rhode
  • G. Sturm

There are no affiliations available

Personalised recommendations